Loading…
Editas Medicine, Inc. is projected to decline to $2.53 by 2027, a -2% move from its current price of $2.58. EDIT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.49 | $2.58 | $2.68 | +0.03% |
| Aug 4 | $2.45 | $2.58 | $2.72 | +0.06% |
| Aug 5 | $2.42 | $2.58 | $2.75 | +0.09% |
| Aug 6 | $2.40 | $2.58 | $2.78 | +0.12% |
| Aug 7 | $2.38 | $2.58 | $2.81 | +0.16% |
| Aug 8 | $2.36 | $2.58 | $2.83 | +0.19% |
| Aug 9 | $2.35 | $2.59 | $2.85 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.35 | $2.59 | $2.85 | +0.22% |
| Week 2 | $2.26 | $2.59 | $2.97 | +0.44% |
| Week 3 | $2.19 | $2.60 | $3.07 | +0.66% |
| Week 4 | $2.14 | $2.60 | $3.16 | +0.88% |
| Week 5 | $2.10 | $2.61 | $3.24 | +1.10% |
| Week 6 | $2.06 | $2.61 | $3.32 | +1.32% |
| Week 7 | $2.02 | $2.62 | $3.39 | +1.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Editas Medicine, Inc. is a clinical stage genome editing company focused on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine, Inc. (EDIT) is currently priced at $2.78 with a market cap of $426.62M and a rank of 3042. The stock sits near a pivotal price level, with the current price trading around the midpoint of its near-term range.
The stock trades with SMA50 at $2.94 and SMA200 at $2.68, providing a sense of near-term momentum relative to longer-term support. RSI14 sits at 40, indicating modest near-term momentum alongside a neutral sentiment.
The 30-day range runs from $2.11 to $3.66, with a defined near-term support at $2.36 and resistance at $3.75. Overall, the technical setup is neutral as investors weigh the potential for periodical volatility.
A major floor 30.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 45.3% above — a clean break opens room to run.
A major ceiling 60.5% above — clearing it would confirm fresh momentum.
Key EDIT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDIT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.63 | Sell | $2.64 | Sell |
| MA 10 | $2.70 | Sell | $2.72 | Sell |
| MA 20 | $3.00 | Sell | $2.84 | Sell |
| MA 50 | $2.92 | Sell | $2.89 | Sell |
| MA 100 | $2.87 | Sell | $2.82 | Sell |
| MA 200 | $2.64 | Sell | $2.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.52 | Neutral |
| Stoch RSI (14) | 12.78 | Buy |
| CCI (20) | -91.31 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -15.13 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 31.60 | Neutral |
| Momentum (10) | -0.40 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.60 | Sell |
| ADX (14) | 17.94 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL. RSI14 at 40 suggests there is room for upside or downside before hitting overbought or oversold levels. The stock trades above the SMA200 of $2.68 but below the SMA50 of $2.94, indicating a balance between longer-term and shorter-term trends.
Near-term support is indicated at $2.36 and resistance at $3.75, with the 30-day range spanning $2.11 to $3.66. This range provides a framework for short-term price action as traders assess catalysts and news flow.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.66 | $2.58 | $3.48 | 0% | Neutral | |
| $1.95 | $2.53 | $3.50 | -2% | Neutral | |
| $2.28 | $3.07 | $4.46 | +19% | Neutral | |
| $3.03 | $4.22 | $6.36 | +63% | Bullish | |
| $2.87 | $4.12 | $6.41 | +60% | Bullish | |
| $2.95 | $4.34 | $6.93 | +68% | Bullish | |
| $3.05 | $4.61 | $7.54 | +79% | Bullish | |
| $2.80 | $4.33 | $7.23 | +68% | Bullish | |
| $3.35 | $5.31 | $9.05 | +106% | Bullish | |
| $3.94 | $6.37 | $11.07 | +147% | Bullish | |
| $4.58 | $8.21 | $15.37 | +218% | Bullish | |
| $7.19 | $15.50 | $32.37 | +501% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.66 | $2.58 | $3.31 | +0.00% |
| September 2026 | $2.27 | $2.72 | $3.36 | +5.27% |
| October 2026 | $2.20 | $2.65 | $3.33 | -2.27% |
| November 2026 | $2.23 | $2.71 | $3.44 | +2.25% |
| December 2026 | $2.22 | $2.71 | $3.48 | -0.04% |
Click any year to see its month-by-month EDIT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDIT to range from $1.66 to $3.48 through 2026. The $2.58 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EDIT price prediction for 2027 points to an average of $2.53 (low $1.95, high $3.50) — a potential decline of -2% on today's $2.58. Price action looks broadly range-bound.
In 2028, EDIT is projected to trade between $2.28 and $4.46, averaging $3.07 — a potential gain of +19% from today's $2.58. That is up +21% on the projected 2027 average. A consolidation phase looks the most probable path here.
Editas Medicine, Inc.'s 2029 outlook centres on $4.22, within a $3.03 to $6.36 range. That is up +37% on the projected 2028 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2030, EDIT could reach as high as $6.41, with a base case around $4.12 and support toward $2.87 — roughly +60% from $2.58. Buyers look set to stay in control over this stretch.
Expect EDIT to range from $2.95 to $6.93 through 2031. The $4.34 average target implies a +68% move from current prices. That is up +5% on the projected 2030 average. Momentum favours further upside here.
The EDIT price prediction for 2032 points to an average of $4.61 (low $3.05, high $7.54) — a potential gain of +79% on today's $2.58. Buyers look set to stay in control over this stretch.
In 2033, EDIT is projected to trade between $2.80 and $7.23, averaging $4.33 — a potential gain of +68% from today's $2.58. That is -6% versus the projected 2032 average. Momentum favours further upside here.
Editas Medicine, Inc.'s 2034 outlook centres on $5.31, within a $3.35 to $9.05 range. That is up +23% on the projected 2033 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, EDIT could reach as high as $11.07, with a base case around $6.37 and support toward $3.94 — roughly +147% from $2.58. Momentum favours further upside here.
Expect EDIT to range from $4.58 to $15.37 through 2040. The $8.21 average target implies a +218% move from current prices. That is up +29% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EDIT price prediction for 2050 points to an average of $15.50 (low $7.19, high $32.37) — a potential gain of +501% on today's $2.58. Momentum favours further upside here.
Investing $1,000 in EDIT today (≈ 387.596899 EDIT) could be worth
$6,007.54
+$5,007.54 (+501%) by 2050 · US Dollar
Based on the average projected EDIT price of $15.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDITwould be worth at today's price.
$1,000 invested in EDIT on Jul 31, 2025 (≈ 398.406376 EDIT) would be worth
$1,027.89
+$27.89 (+2.8%) today · 1.03× · US Dollar
Based on a EDIT entry price of $2.51 vs. today's $2.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.6 | $992.31 | -0.8% |
| 1 month ago | $3.28 | $786.59 | -21.3% |
| 3 months ago | $2.9 | $889.66 | -11.0% |
| 6 months ago | $2.01 | $1,283.58 | +28.4% |
| 1 year ago | $2.51 | $1,027.89 | +2.8% |
| All time (5.0y) ago | $42.11 | $61.27 | -93.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDIT forecast.
Our base-case forecast reaches $5.20 around 2034.
Implied market cap at $5.20: $798M
The multi-year forecast shows a path from a flat 2026 to a pronounced bull run in later years. For 2030 the forecast shows an average price of $4.55 with a max of $7.31 and a min of $3.07, corresponding to a 63.6% ROI and a bullish sentiment. By 2040 the average price is forecast at $9.58 with a max of $18.83 and a min of $4.96, producing a 244.7% ROI and a bullish sentiment.
In 2050 the average is projected to $17.19 with a max of $37.93 and a min of $7.74, delivering a 518.3% ROI and a bullish sentiment.
The outlook from 2028 onward shows continued bullish momentum, with higher average prices and robust ROI projections through 2050. These figures are estimates and not guarantees, and actual results will depend on a range of factors including clinical progress, regulatory outcomes, and market conditions.
Tap a question to reveal the answer.
2030 forecast: min $3.07, avg $4.55, max $7.31, ROI 63.6%, sentiment BULLISH.
The forecast shows a path from neutral in 2026 (avg $2.78, ROI 0) to bullish in later years, with 2040 avg $9.58 (ROI 244.7%) and 2050 avg $17.19 (ROI 518.3%). These are estimates, not guarantees, and involve risk.
Yes. The 2032 forecast shows an average around $5.10 with a max of $8.65. Additionally, 2034 forecasts an average of $6.03 and a max of $10.71, indicating potential to exceed $5 in the forecast path.
Current price: $2.78. Market cap: $426.62M.
RSI14 is 40, SMA50 is $2.94, SMA200 is $2.68. The 30-day range is $2.11 to $3.66, with support at $2.36 and resistance at $3.75.
Editas Medicine, Inc. Community Discussion
0Share your Editas Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.